If this message is not displayed correctly, click here.


No 90, November 2016


The  presentations of the ESC/ERA-EDTA Joint Symposium at the ESC Congress 2016 are on ENP!

Log in to the European Nephrology portal (ENP) and have a look at the presentations given during the ESC/ERA-EDTA Joint Symposium at the ESC Congress 2016 that was held in Rome (Italy). Enter the Joint Sessions’ section and enjoy these four presentations! Click here!

Still not registered for ENP? Click here and do it now!

ERA-EDTA at ASN Kidney Week

ERA-EDTA is at ASN's Kidney Week

ERA-EDTA will be present at the Scientific Exposition of ASN’s Kidney Week that will take place at the McCormick Place in Chicago from November 17 to November 20. Visitors will be able to meet ERA-EDTA staff and receive the latest information about the 54th ERA-EDTA Congress in Madrid and other activities of the association at booth 1528, from 9.30 am to 2.30 pm on November 17-18-19, 2016. The exhibition will also be open on November 17th from 6.30 to 7.30 pm! You may apply for ERA-EDTA membership or to renew it at the booth.
If you will be in Chicago, please do not miss the Special Session on the Highlights from the 2016 ERA-EDTA Congress in Vienna! Click here to have a look at the full session programme.

Just published online! Read the latest NDT and CKJ articles

Just published online! Read the latest NDT and CKJ articles

Enhancing primary care by electronic diagnosis and management assistance devices?
Often, the primary care of patients with chronic kidney disease does not meet the criteria of best practice. In order to improve primary care of these patients an electronic diagnosis and management assistance device was tested by an Australian research group. It was shown that the program improved the identification of patients at risk of CKD as well as the appropriate testing and management of these patients. The authors of the newly published study claimed: “We have demonstrated efficacy in overcoming the verified gap between current and best practice in primary care.”

Read More →

Rituximab reduced relapse rate in patients with NS due to minimal change diseaseMeasuring GFR by iohexol as a new diagnostic standard?
Although nephrotic syndromes (NS) due to minimal change disease occur rather randomly, they often represent a therapeutic challenge in clinical practice. 25% of patients have frequently relapsing NS and 30% become steroid dependent – and the standard treatment goes along with high toxicity. Therefore, a British study group tested the efficacy and safety of rituximab (RTX) in 13 patients with this diagnosis. The small study showed a promising result: After treatment with RTX, the rate of relapse was reduced from 4 to 0.4/year (p ≤ 0.05). Might this impact the future treatment recommendations?

Read More →

Have you read the latest issue of Follow Us?

The Follow Us newsletter is NOW available in a NEW electronic format.  Click here to read the latest issue.

The Scientific Programme for Madrid, the European Activation Committees, the European Certificate in Nephrology and the 2017 call for Council candidates are just some of the topics covered in the November edition.

The Follow Us newsletter provides information about ERA-EDTA's activities, initiatives and people; it is also a form for sharing anecdotes and perspectives.  If you have an interesting and relevant story that you wish to share please get in touch at followus@era-edta.org

ERA-EDTA Flash is the official ERA-EDTA eNewsletter

Editor-in-Chief: Mustafa Arici
Editorial Secretariat: Valentina Cocchi
Newsletter Design: Ilaria Martini

ERA-EDTA Headquarters
Via XXIV Maggio, 38
43123 Parma - Italy

The ERA-EDTA collects and processes personal information to provide you with details regarding the Association and its activities. The information is used for accounting and commercial purposes by ERA-EDTA and/or Euromeetings s.r.l. in compliance with the Italian Legislative Decree 196/2003. If at any time you wish to change personal information that is incorrect or wish to have your personal data deleted, please REPLY this email and specify ‘REMOVE ME FROM YOUR DATABASE’. ERA-EDTA will meet such requests at the earliest possible opportunity by deleting or amending your personal information.